It's a single drug and they've only made public their...

It's a single drug and they've only made public their plan for GBM as per the attached pics. Keeping in mind they've got the comprehensive IP patented for the chlorotoxin and they've been pretty blunt about exploring IND status opportunities for melanoma and other solid tumours throughout the year - can't predict that timeline and will happen whenever it happens at random. When phase 1 has stopped enrolling you'd imagine an update too (6 month progression permitting, that would be soon if it wraps up September).

Phase 1 trials done September, phase 2's in October straight after and the interim read outs will be provided to the market.

YouTube CHM Chimeric NWR for a run down or skim through Edison's analyst report with a $.93 price target from memory.

This is a bottom drawer stock imo, but also don't disagree with waiting until phase 1 results are out - just expect to be paying at much higher premiums. a left of field melanoma update will open up a big market and further demonstrate the co's conviction.

Remembering this ran to $0.4 on no news, with news this will run way higher and fast. I'm not ready to trade this for pips in these early stages. Been there, done that, missed out.